ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies
Status:
Withdrawn
Trial end date:
2020-02-03
Target enrollment:
Participant gender:
Summary
This research is studying the safety of combining ibrutinib with the study drug LY3214996 for
chronic lymphocytic leukemia (CLL), Waldenstrom's macroglobulinemia (WM), mantle cell
lymphoma (MCL), or marginal zone lymphoma (MZL).